Thomas L. Ingram

Nessuna posizione attualmente

69 anni

Commercial Services

Consumer Services

Profilo

Thomas L.
Ingram worked as a Director at Venturis Therapeutics, Inc. and as an Office Manager at Troster Singer Corp.
from 1984 to 1997.
He obtained an undergraduate degree from Pepperdine University.

Precedenti posizioni note di Thomas L. Ingram

Società	Posizione	Fine
Troster Singer Corp.	Corporate Officer/Principal	01/01/1997
Venturis Therapeutics, Inc. Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di Thomas L. Ingram

Formazione di Thomas L. Ingram

Pepperdine University

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Thomas L. Ingram

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Venturis Therapeutics, Inc. Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.	Commercial Services
Troster Singer Corp.